Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
1. Histologically documented diagnosis of GBM.
2. Immunohistochemical documentation of expression of PDGFR.
3. Unresectable, recurrent disease by MRI and spectroscopy
1. Treatment with any other investigational agents within 28 days of first day of study
2. Concurrent chemotherapy.
3. Concurrent radiotherapy.
Other protocol-defined exclusion criteria may apply.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months
Brazil: National Health Surveillance Agency
- Brain tumors